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The most troublesome complication of acute pericarditis is recurrent pericardial inﬂammation, which occurs
in 15%–32% of cases. The optimal method for prevention has not been fully established; accepted
modalities include nonsteroidal anti-inﬂammatory drugs, corticosteroids, immunosuppressive agents, and
pericardiectomy. Over the last years, objective clinical evidence has matured and clearly indicates the
important role and beneﬁcial clinical effect of colchicine therapy in preventing recurrent pericarditis caused
by various etiologies. Colchicine-treated patients consistently display signiﬁcantly fewer recurrences and
longer symptom-free periods, and even when attacks occur, they are weaker and shorter in nature. Notably,
pretreatment with corticosteroids substantially attenuates the efﬁcacy of colchicine, causing signiﬁcantly
more recurrences and longer therapy periods. The safety proﬁle seems superior to other drugs, such as
corticosteroids and immunosuppressive drugs. Colchicine is a safe and effective modality for the treatment
and prevention of recurrent pericarditis, especially as an adjunct to other modalities, because it provides a
sustained beneﬁt, superior to all current modalities.
Introduction
Pericardial inflammation is not a rare disorder. It is
characterized by a combination of clinical signs, symptoms,
and diagnostic tests such as electrocardiography (ECG) and
chemical blood analyses. Practically, the etiology remains
obscure in most cases, although many causes have been
identified. Usually, pericarditis manifests acutely but can
further evolve in up to third of the cases to chronic or
recurrent forms. The management of pericarditis generally
includes treatment of the acute phase and prevention of
further episodes. Much attention has been given in the
last several decades to identification of new and efficient
preventive measures for recurrent episodes of pericarditis.
Here we review the potential use of the drug colchicine,
which has been proven efficacious in familialMediterranean
fever and in the prevention of recurrent pericarditis, and
comment on the current European guidelines accordingly.
Acute Pericarditis
Acute pericarditis (AP) is an inflammatory disease of
the epicardium, diagnosed in 1 in every 1000 hospital
admissions in the United States.1 Diagnosis of AP is based
on the presence of ≥2 of the following clinical and/or
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laboratory findings: pleuritic chest pain, pericardial friction
rub, widespread saddle-shaped or concave upward ST-
segment elevation or PR-segment depression on the ECG,
and new or worsening pericardial effusion. Elevation of
inflammatory markers, such as C-reactive protein, is useful
to confirm the clinical suspicion. Several etiologies may
account for AP, including viral, bacterial, and autoimmune
etiologies as well as postpericardiotomy, post–myocardial
infarction, cardiac trauma, and neoplasm. In the majority of
cases (about 85%), the etiology remains unknown also after
exclusion of the main specific causes (tuberculous, other
bacterial, neoplastic, related to connective-tissue diseases),
and they are labeled idiopathic. A recent prospective study
on 500 AP patients showed that development of constrictive
pericarditis is a rare complication of viral or idiopathic
forms,whereas it is relatively frequent for specific etiologies,
such as tuberculous pericarditis (20%–25%; 31.65 cases per
1000 person-years) and purulent pericarditis (30%–33%; 52.7
cases per 1000 person-years).2 Treatment usually consists of
aspirin or a nonsteroidal anti-inflammatory drug (NSAID),
corticosteroids, and treatment of the underlying cause,
when possible.1 Corticosteroid therapy has few specific
indications in autoimmune and autoreactive forms, and
when aspirin or NSAID is contraindicated.
Recurrent Pericarditis
Recurrent pericarditis (RP) is generally manifested by
recurrence of AP symptoms after resolution and elimination
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of the inciting agent.3–5 Recurrent pericarditis develops
in 15%–32% of AP patients not treated with colchicine,3,6,7
usually within 18–20 months after the initial AP episode,
but it also may occur after longer periods.6,8 The disease
usually has a relapsing-remitting pattern3–5 but may be
more chronic in some cases.9 Recurrent pericarditis
was defined in the Colchicine for Recurrent Pericarditis
(CORE) study as the combination of a documented initial
AP attack with evidence of either recurrence or, less
often, persistent pericarditis.10 The definition of recurrence
includes pleuritic chest pain (most common symptom) and
≥1 of the following signs: fever, pericardial friction rub,
ECG changes, echocardiographic evidence of pericardial
effusion, and an elevation in the white blood cell count,
erythrocyte sedimentation rate, or C-reactive protein.10
Elevated markers of inflammation confirm the diagnostic
suspicion. There is a considerable variability in the number
of recurrences and in the length of remission intervals
among patients. Up to 50% have only 1–2 recurrences,8,10
usually over several months to a few years, or, in some
cases, as long as 15 years.3 Tamponade and constrictive
pericarditis are rare complications, even in patients who
had tamponade during the initial episode,11 and seldom
lead to cardiomyopathy.3,11 Idiopathic forms of recurrence
have a very good prognosis without risk of constriction,
even if there were several recurrences.12
Most clinicians and investigators regard RP as an autoim-
mune phenomenon, based on serological findings and
frequent responsiveness to immunosuppressive therapy.
However, European investigators have recently demon-
strated a higher prevalence of infectious etiology (infection
or reinfection) by employing pericardioscopy, epicardial
biopsy, and polymerase chain reaction.9,13 Autoreactive
pericarditis can be determined only if other etiolo-
gies (infectious, neoplastic, systemic, or metabolic) have
been excluded and pericardial fluid analysis reveals sev-
eral immunological features, including increased number
of mononuclear cells, antisarcolemmal antibodies, and
inflammatory cytokines (interleukin-6, interleukin-8, and
interferon-γ).9,13 Clinical features have a limited yield in
predicting the development of RP, but lack of response to
NSAID treatment increases the risk for RP and pericardial
constriction.7 Similarly, inappropriate corticosteroid ther-
apy in AP promotes development of RP, possibly due to
enhanced viral replication.6,10,14,15
Treatment
Treatment of RPmay be prolonged and requires compliance
and effective communication with the patient. Therapeu-
tic modalities include NSAIDs, colchicine, corticosteroids,
intrapericardial therapy, and pericardiectomy. The 2004
European Society of Cardiology guidelines issued a class
I recommendation for the use of NSAIDs to treat AP (see
Appendix).16 High-dose short-term corticosteroid therapy
usually induces remission but requires prolonged or fre-
quent administration, potentially leading to serious compli-
cations and even to an increased rate of recurrence.6,10,15,17
Therefore, it is recommended that the use of steroids for
RP should be limited. Moreover, the experience from treat-
ing serositis in other autoimmune forms suggests that lower
doses, such as 25–50 mg of prednisone/day, may be equally
effective to treat the disease with less-severe side effects.18
In this review we will focus on the role of colchicine in the
prevention and treatment of RP.
Colchicine
Colchicine is an alkaloid drug that is effectively used in
several inflammatory diseases, such as familial Mediter-
ranean fever, chronic gout, andBeh¸ et syndrome.Colchicine
inhibits tubulin polymerization, thereby inhibitingmigration
of polymorphonuclear cells into inflamed sites and decreas-
ing metabolic activity and phagocytosis to efficiently break
the inflammation cycle.
The beneficial effect of colchicine in RPwas demonstrated
in a 1990 study of 9 patients who had ≥3 recurrences
either on NSAID or corticosteroid treatment.19 Although
the symptom-free period before initiation of colchicine
treatment was 3.3 months, none of the patients exhibited
a recurrence after treatment during a mean follow-up of
24.3 months (P< 0.002).19 Similar results were observed in
another study of 8 RP patients who were treated either with
a combination of NSAIDs and corticosteroids (6/8 patients)
or with corticosteroids followed by pericardiocentesis (2/8
patients). Themean symptom-free period before initiation of
colchicine treatment was 6 months, and 26 months during
follow-up on colchicine.20
A multicenter international review of the efficacy of
1 mg/day colchicine in 51 patients with 187 recurrences,
despite conventional treatment with NSAIDs and corticos-
teroids, and a mean symptom-free period of 3 months, has
demonstrated remarkable results.21 Indeed, only 7 patients
exhibited a total of 10 minor clinical relapse events on
colchicine treatment over 36 months of follow-up; half of
these events occurred after corticosteroids were stopped.
Colchicine was discontinued in 39 patients, of whom 14
(36%) relapsed, with a total of 10 events within 1 month
or with a total of 17 events within 1 year of cessation of
colchicine. It is noteworthy that all recurrences were clini-
cally minor. The beneficial effect of colchicine was evident
by the increasing symptom-free period both during treat-
ment (3.1 mo vs 17.8 mo, P< 0.001) and after treatment (3.1
mo vs 30.3 mo, P< 0.001); the symptom-free period globally
was 3.1–43 months (P< 0.001). Furthermore, it was found
that the use of colchicine with or without NSAIDs reduces
or eliminates the need for corticosteroids in patients with
RP, as the number of recurrences decreased from 4.5 to 2.5
(P< 0.001) and the period of colchicine treatment itself was
considerably shortened, from 28.3 months to 8.4 months.21
The first significant data came from the randomized
CORE study, in which 84 consecutive patients with a
first episode of RP were randomly assigned to 1 month
aspirin either alone or in combination with colchicine for
6 months.10 Colchicine therapy was safe, did not exhibit any
significant toxicity, and resulted in an impressive clinical
outcome. Colchicine-treated patients displayed a marked
and significant reduction in the primary endpoint of the
actuarial rate of recurrence at 18 months (24% vs 51%) and a
significant reduction in the secondary endpoint of symptom
persistence at 72 hours (10% vs 31%), when compared with
aspirin alone.10 Similar benefits were noted with colchicine
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in the Colchicine for Acute Pericarditis (COPE) trial of
patients with a first episode of acute, usually idiopathic,
pericarditis.6 In addition, a potential benefit for colchicine
has been shown in the prevention of postpericardiotomy
syndrome in patients after cardiac surgery (10.6% vs 21.9%
placebo, P < 0.135).22 Further evaluations in larger clinical
trials are warranted. The use of colchicine in addition
to an NSAID or as monotherapy for RP was given a
class I recommendation by the 2004 European Society
of Cardiology guidelines.16 Importantly, previous therapy
with corticosteroids in the CORE study was an independent
predictor of further recurrences after colchicine therapy.10
Recently, the Colchicine for Recurrent Pericarditis (CORP)
trial, a prospective, randomized, double-blind, placebo-
controlledmulticenter trial, evaluated the efficacy and safety
of colchicine for the secondary prevention of recurrent
pericarditis in 120 RP patients.23 Patients were randomly
assigned to receive either placebo or colchicine, in addition
to conventional therapy. Remarkably, the recurrence rate
was 24% in the colchicine group and 55% in the placebo group
at 18 months (absolute risk reduction, 0.31 [95% confidence
interval {CI}: 0.13-0.46]; relative risk reduction, 0.56 [95%
CI: 0.27-0.73]; number needed to treat, 3 [95% CI: 2-7]).
Colchicine also reduced the persistence of symptoms at
72 hours (absolute risk reduction, 0.30 [95% CI: 0.13-0.45];
relative risk reduction, 0.56 [95% CI: 0.27-0.74]) and mean
number of recurrences, increased the remission rate at 1
week, and prolonged the time to subsequent recurrence.
There were no differences in rates of side effects and drug
withdrawal.23
Another study shows that pretreatment with corti-
costeroids attenuates the beneficial effect of colchicine
treatment.17 This international multicenter study included
119 patients under full colchicine treatment, for up to
185 months of follow-up (71 were treated with corticos-
teroids prior to the study and 48 patients were not). A
substantially higher percentage of patients treated with cor-
ticosteroids relapsed among the 71 patients, both during
colchicine treatment (20% vs 10%) and after colchicine was
discontinued (40% vs 10%). The striking differences between
the 2 groups, steroids vs no steroids, were further evident
in the length of the required treatment with colchicine
(24.5 mo vs 9.7 mo, respectively, P = 0.001) and in relapses
per patient (0.65 vs 0.18, respectively, P = 0.006).17 Impor-
tantly, there were 2 relapses per patient in the steroid
group as compared with the no-steroid group (5.1 vs 2.81,
respectively, P = 0.001). No correlation between the num-
ber of relapses/patient and any continuous parameter could
be identified. Multivariate logistic regression analysis for
prediction of having relapses after colchicine treatment
was statistically significant for male sex (odds ratio: 4.2,
P = 0.03) and previous corticosteroid treatment (odds ratio:
6.7, P = 0.01).16
Recently, further positive lines of evidence for the
role of colchicine in prevention of perdicardial disease
were obtained. The Colchicine for the Prevention of
the Postpericardiotomy Syndrome (COPPS) study,24 a
multicenter, double-blind, randomized trial, tested 360
patients who were randomized to receive on third day
postpericardiectomy for placebo or colchicine. Remarkably,
colchicine significantly reduced the incidence of the
postpericardiotomy syndrome at 12 months compared with
placebo (respectively, 8.9 vs 21.1%, P = 0.002; number
needed to treat, 8). Colchicine also reduced the secondary
endpoint, which included the combined rate of disease-
related hospitalization, cardiac tamponade, constrictive
pericarditis, and relapses, as compared with placebo
(respectively, 0.6 vs 5.0%, P = 0.024).
Moreover, an additional beneficial preventive effect of
colchicine in the postoperative setting is also its possi-
ble capability to prevent postoperative atrial fibrillation.
Colchicine administration significantly reduced the inci-
dence of postoperative atrial fibrillation (12.0% vs 22.0%,
respectively, P = 0.021; relative risk reduction, 45%; num-
ber needed to treat, 11), with a shorter in-hospital stay (9.4
± 3.7 d vs 10.3 ± 4.3 d, P = 0.040) and rehabilitation stay
(12.1 ± 6.1 d vs 13.9 ± 6.5 d, P = 0.009).25 There were
no significant differences in the rate of side effects in the
colchicine and placebo groups (respectively, 8.9 vs 5.0%,
P = 0.212).24,25 The beneficial role of colchicine in preven-
tion of postpericardiotomy pericarditis was concomitantly
suggested by a meta-analysis conducted on available data.26
Precautions and Future Research
Although colchicine at low doses (0.5–1.2 mg/d) has been
found to be safe evenwhengiven continuously over decades,
there are other less-common (<1%) possible side effects
to be considered (bone-marrow suppression, hepatotoxi-
city, myotoxicity) beyond the well-known gastrointestinal
side effects encountered in 5%–10% of cases. Chronic
renal insufficiency leading to increased colchicine levels
appears to be the major risk factor for side effects and
other possible negative interactions. Colchicine is also a
substrate of P-glycoprotein, a transporter involved in the
elimination of several drugs. Macrolides are inhibitors of
P-glycoprotein and cytochrome P450–dependent enzymes
and may decrease colchicine excretion. Coadministration of
colchicine and macrolides may impair colchicine elimina-
tion, resulting in possible drug excess, particularly in the
elderly and those with renal insufficiency.
At present, it seems reasonable to avoid the coadminis-
tration of colchicine and macrolides. It is also prudent to
reduce the maintenance/prophylactic dose by 50% in indi-
viduals age >70 years and in patients with impaired renal
function and glomerular filtration rates <50 mL/minute.
Every patient should undergo a careful monitoring of pos-
sible side effects, including blood analyses (transaminases,
serum creatinine, creatine kinase, and blood cell count)
before starting the drug, and later after at least 1 month of
treatment. Further studies are required to validate the use of
colchicine in AP probably when caused by certain etiologies,
whereas stronger evidence supports its use in RP.27–30
Conclusion
Colchicine is a safe and effective modality for the treatment
and prevention of recurrent pericarditis, especially as an
adjunct to other modalities, because it provides a sustained
benefit superior to all current modalities. Moreover, the
safety profile seems more favorable than those of other
drugs, such as corticosteroids and immunosuppressive
drugs.
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Appendix
Colchicine regimen: recommendations of the European
Society of Cardiology:
• Dose of 2 mg/day for 1 or 2 days, followed by
a maintenance dose of 1 mg/day. Use of loading
dose is controversial (may increase the risk of side
effects), whereas lower maintenance doses such as
0.5 mg/day may be equally effective with fewer side
effects (above all in patients <70 kg). Recurrent
pericarditis patients should be treated with aspirin
or another nonsteroidal anti-inflammatory drug plus
colchicine (1–2 mg on the first day, followed by
0.5 once or twice daily for 6 months). The lower
colchicine dose (1 mg initial dose followed by 0.5 mg
once daily) is given to patients who weigh <70 kg
or who do not tolerate the higher dose. A practical
approach is to use low starting doses (0.5 mg/d),
then increasing up to 0.5 mg twice a day in patients
>70 kg, if tolerated. Avoiding the loading dose may
improve the compliance.
• Maintenance/prophylactic dose should be reduced
by 50% in individuals age >70 years and in patients
with glomerular filtration rates <50 mL/minute.
• All patients should undergo a careful monitoring
of possible side effects, including blood analyses
(transaminases, serum creatinine, creatine kinase,
and blood cell count) before initiation of therapy, and
after at least 1 month of treatment.
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